Tesamorelin peptide is an FDA-approved growth hormone-releasing hormone analog that reduces visceral belly fat in adults with HIV-related lipodystrophy.
Tesamorelin is a man-made peptide that mimics growth hormone-releasing hormone (GHRH), signaling the pituitary gland to release more growth hormone. It is FDA-approved under the brand name Egrifta SV to reduce visceral abdominal fat in adults with HIV-associated lipodystrophy. It is not a steroid, not a GLP-1 weight-loss drug, and not growth hormone itself.
What Is Tesamorelin Peptide in Plain Terms?
Tesamorelin is a 44-amino-acid peptide built from the full sequence of human GHRH, with a small modification that helps it survive longer in the bloodstream. Because it is a peptide rather than a steroid, it does not bind androgen receptors and does not build muscle directly.
Key facts about tesamorelin peptides:
- Drug class: Growth hormone-releasing hormone (GHRH) analog.
- Brand name: Egrifta SV, a prescription injectable.
- Approved use: Excess visceral abdominal fat in HIV-associated lipodystrophy.
- Delivery: Once-daily subcutaneous injection.
- Legal status: Prescription-only in the US; not a DEA-controlled substance.
What Does Tesamorelin Do? How Tesamorelin Works
Tesamorelin binds GHRH receptors on pituitary cells and prompts them to release growth hormone in pulses, much like the body's own GHRH does. That growth hormone then travels to the liver and other tissues, raising IGF-1 and changing how the body stores and breaks down fat.
This indirect route is the heart of the tesamorelin mechanism of action: it amplifies your own hormone signaling instead of replacing it. The result is a preference for shrinking visceral (deep belly) fat rather than fat just under the skin.
People comparing secretagogues often ask what is ipamorelin peptide or what is cjc 1295 peptide, since those compounds also nudge growth hormone release through different receptor pathways.
Is Tesamorelin a Steroid, a GLP-1, or Growth Hormone?
No to all three. Tesamorelin is not an anabolic steroid, it is not a GLP-1 receptor agonist like semaglutide or tirzepatide, and it is not recombinant growth hormone. It occupies its own category: a GHRH analog peptide.
| Compound | What It Is | Primary Action | Typical Use |
|---|---|---|---|
| Tesamorelin | Synthetic GHRH analog peptide | Stimulates pituitary growth hormone release | Prescription: visceral fat in HIV lipodystrophy |
| Anabolic steroids | Testosterone derivatives | Bind androgen receptors | Hormone therapy, muscle growth |
| GLP-1 agonists | Incretin-based peptides | Increase insulin release, slow gastric emptying, curb appetite | Type 2 diabetes, weight management |
| Recombinant HGH | Growth hormone protein | Directly raises GH and IGF-1 | Growth hormone deficiency |
The practical takeaway: if a vendor markets tesamorelin as "HGH" or as a GLP-1 alternative, that description is inaccurate.
What Is Tesamorelin Peptide Used For?
The only FDA-approved use is reducing visceral adipose tissue in adults with HIV-associated lipodystrophy, a condition in which fat redistributes to the abdomen and neck. It is prescribed alongside diet and exercise, not as a replacement for them.
Off-label, bodybuilders and biohackers use tesamorelin peptides during cutting phases and body recomposition. The Spanish-language search tesamorelin para que sirve asks the same question, and the answer is the same: there is no approved use for general weight loss.
- Approved: Visceral fat reduction in HIV-associated lipodystrophy, in combination with diet and exercise.
- Off-label and unproven: Fat loss in healthy adults, body recomposition, anti-aging protocols.
- Not indicated for: Muscle building, general obesity, or athletic performance.
Does Tesamorelin Work? What the Research Shows
In randomized trials, daily tesamorelin reduced visceral adipose tissue by roughly 15 to 20 percent over 26 weeks in people with HIV lipodystrophy, with smaller changes in waist circumference. Those fat reductions reversed after treatment stopped.
There is no large, high-quality trial showing that tesamorelin produces meaningful weight loss or muscle gain in healthy people who already train and eat well. So whether tesamorelin works depends on the goal: the evidence is solid for the approved condition and thin for fitness uses.
Tesamorelin Dosage, Side Effects, and Safety
The approved dose is 1.4 mg (Egrifta SV) injected subcutaneously once daily, usually in the abdomen with rotating injection sites. A healthcare provider sets the dose and monitors IGF-1 levels and blood sugar during treatment.
Side effects reported in clinical trials include:
- Injection site reactions such as redness, pain, or irritation
- Joint pain and muscle pain
- Swelling in the hands and feet (edema)
- Numbness or tingling similar to carpal tunnel symptoms
- Changes in blood sugar and glucose tolerance
Tesamorelin is not appropriate during pregnancy, with active cancer, or after pituitary surgery or radiation. Because it raises growth hormone and IGF-1, it can affect glucose metabolism and carries a label warning about diabetes risk. Anyone considering it should speak with a licensed healthcare professional first.
Tesamorelin Legality and Sourcing
Tesamorelin requires a prescription in the United States and is not classified as a controlled substance. Online "research peptide" listings sold for laboratory use are not FDA-reviewed for purity, sterility, or dosage accuracy, and they are not legal for human consumption.
Other compounds studied in the same research space include what is bpc 157 peptide and what is semax peptide used for, along with what is delta sleep inducing peptide — but those target tissue repair, cognition, and sleep rather than visceral fat.
Frequently Asked Questions
Is tesamorelin a steroid?
No. Tesamorelin is a synthetic peptide that mimics growth hormone-releasing hormone, so it does not bind androgen receptors the way anabolic steroids do. It is also not classified as a controlled substance in the United States, though it does require a prescription.
What is tesamorelin peptide used for?
Its only FDA-approved use is reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, combined with diet and exercise. It is used off-label for fat loss and body recomposition, but those uses lack strong clinical evidence. It is not approved for general weight loss or muscle building.
How long does tesamorelin take to work?
In clinical trials, measurable reductions in visceral fat appeared after about 13 weeks and were most pronounced at 26 weeks of daily injections. Fat returned after participants stopped treatment, so results depend on continued use and ongoing lifestyle habits. Any use should be supervised by a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.